Ad
related to: global initiative for asthma gina global strategy for asthma man
Search results
Results From The WOW.Com Content Network
GINA conducts continuous review of scientific publications on asthma and is a leader in disseminating information about the care of patients with asthma. [2] GINA publishes resources such as evidence-based guidelines for asthma management, and runs special events such as World Asthma Day. GINA's guidelines, revised each year, are used by ...
An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...
Asthma is now recognised as a heterogenous condition by the Global Initiative for Asthma (GINA), [4] and as an umbrella term encompassing multiple different diseases by many scientists. [ 1 ] [ 3 ] This is because multiple different pathological processes amenable to different therapies and with different long-term prognoses and complications ...
World Asthma Day is an annual event organized by the Global Initiative for Asthma (GINA) to improve asthma awareness and care around the world. World Asthma Day is held on the first Tuesday in May. [1] [failed verification] [2] The theme of 2021's event was "Uncovering Asthma Misconceptions," and for 2022, "Closing Gaps in Asthma Care." [2]
Asthma Canada; Asthma UK; G. Global Initiative for Asthma; N. Norwegian Asthma and Allergy Association This page was last edited on 10 January 2023, at 19:52 (UTC ...
It is defined by the Global Initiative for Asthma as "a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. The chronic inflammation is associated with airway hyper-responsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing particularly at night or in ...
2017: Inclusion in GINA. For the first time, allergy immunotherapy is recommended as a treatment option in the Global Initiative for Asthma (GINA) strategy document. [33] 2017: New transformational growth strategy. ALK launches a new strategy to reach out to more people with allergy to become a broader-based allergy company. [33]
In 2000-2001 asthma prevalence was monitored at 6.5%; by 2010-2011 a 4.3% increase was shown, with asthma prevalence totaling 10.8% of Canada's population. [29] Furthermore, asthma prevalence varies among the provinces of Canada; the highest prevalence is Ontario at 12.1%, and the lowest is Nunavut at 3.8%. [29]